1.Microangiopathic Hemolytic Anemia: A Rare Complication of Acute Pancreatitis
Syedda AYESHA ; Masood Muhammad KARIM ; Maria ALI ; Abdul Hadi SHAHID ; Salman Naseem ADIL
The Korean Journal of Gastroenterology 2025;85(1):73-77
Microangiopathic hemolytic anemia (MAHA) is a rare subtype of hemolytic anemia characterized by elevated hemolytic markers and red blood cell destruction. Though uncommon, MAHA can occur as a complication of acute pancreatitis because of the associated inflammatory response. Patients with MAHA secondary to pancreatitis show favorable outcomes when treated with plasma exchange.This paper presents the case of a patient diagnosed with acute pancreatitis-induced hemolytic anemia and thrombocytopenia, who was managed successfully with plasma exchange, steroids, and rituximab. Clinicians should maintain a high index of suspicion in patients with acute pancreatitis who present with anemia, thrombocytopenia, and schistocytes on peripheral smears, even in the absence of end-organ injuries and with normal ADAMTS13 activity. The early initiation of plasmapheresis can be lifesaving. The timely introduction of rituximab in cases where plasma exchange and steroids are insufficient, despite the ADAMTS13 activity status, may lead to better outcomes.
2.Microangiopathic Hemolytic Anemia: A Rare Complication of Acute Pancreatitis
Syedda AYESHA ; Masood Muhammad KARIM ; Maria ALI ; Abdul Hadi SHAHID ; Salman Naseem ADIL
The Korean Journal of Gastroenterology 2025;85(1):73-77
Microangiopathic hemolytic anemia (MAHA) is a rare subtype of hemolytic anemia characterized by elevated hemolytic markers and red blood cell destruction. Though uncommon, MAHA can occur as a complication of acute pancreatitis because of the associated inflammatory response. Patients with MAHA secondary to pancreatitis show favorable outcomes when treated with plasma exchange.This paper presents the case of a patient diagnosed with acute pancreatitis-induced hemolytic anemia and thrombocytopenia, who was managed successfully with plasma exchange, steroids, and rituximab. Clinicians should maintain a high index of suspicion in patients with acute pancreatitis who present with anemia, thrombocytopenia, and schistocytes on peripheral smears, even in the absence of end-organ injuries and with normal ADAMTS13 activity. The early initiation of plasmapheresis can be lifesaving. The timely introduction of rituximab in cases where plasma exchange and steroids are insufficient, despite the ADAMTS13 activity status, may lead to better outcomes.
3.Microangiopathic Hemolytic Anemia: A Rare Complication of Acute Pancreatitis
Syedda AYESHA ; Masood Muhammad KARIM ; Maria ALI ; Abdul Hadi SHAHID ; Salman Naseem ADIL
The Korean Journal of Gastroenterology 2025;85(1):73-77
Microangiopathic hemolytic anemia (MAHA) is a rare subtype of hemolytic anemia characterized by elevated hemolytic markers and red blood cell destruction. Though uncommon, MAHA can occur as a complication of acute pancreatitis because of the associated inflammatory response. Patients with MAHA secondary to pancreatitis show favorable outcomes when treated with plasma exchange.This paper presents the case of a patient diagnosed with acute pancreatitis-induced hemolytic anemia and thrombocytopenia, who was managed successfully with plasma exchange, steroids, and rituximab. Clinicians should maintain a high index of suspicion in patients with acute pancreatitis who present with anemia, thrombocytopenia, and schistocytes on peripheral smears, even in the absence of end-organ injuries and with normal ADAMTS13 activity. The early initiation of plasmapheresis can be lifesaving. The timely introduction of rituximab in cases where plasma exchange and steroids are insufficient, despite the ADAMTS13 activity status, may lead to better outcomes.
4.Microangiopathic Hemolytic Anemia: A Rare Complication of Acute Pancreatitis
Syedda AYESHA ; Masood Muhammad KARIM ; Maria ALI ; Abdul Hadi SHAHID ; Salman Naseem ADIL
The Korean Journal of Gastroenterology 2025;85(1):73-77
Microangiopathic hemolytic anemia (MAHA) is a rare subtype of hemolytic anemia characterized by elevated hemolytic markers and red blood cell destruction. Though uncommon, MAHA can occur as a complication of acute pancreatitis because of the associated inflammatory response. Patients with MAHA secondary to pancreatitis show favorable outcomes when treated with plasma exchange.This paper presents the case of a patient diagnosed with acute pancreatitis-induced hemolytic anemia and thrombocytopenia, who was managed successfully with plasma exchange, steroids, and rituximab. Clinicians should maintain a high index of suspicion in patients with acute pancreatitis who present with anemia, thrombocytopenia, and schistocytes on peripheral smears, even in the absence of end-organ injuries and with normal ADAMTS13 activity. The early initiation of plasmapheresis can be lifesaving. The timely introduction of rituximab in cases where plasma exchange and steroids are insufficient, despite the ADAMTS13 activity status, may lead to better outcomes.
5.Microangiopathic Hemolytic Anemia: A Rare Complication of Acute Pancreatitis
Syedda AYESHA ; Masood Muhammad KARIM ; Maria ALI ; Abdul Hadi SHAHID ; Salman Naseem ADIL
The Korean Journal of Gastroenterology 2025;85(1):73-77
Microangiopathic hemolytic anemia (MAHA) is a rare subtype of hemolytic anemia characterized by elevated hemolytic markers and red blood cell destruction. Though uncommon, MAHA can occur as a complication of acute pancreatitis because of the associated inflammatory response. Patients with MAHA secondary to pancreatitis show favorable outcomes when treated with plasma exchange.This paper presents the case of a patient diagnosed with acute pancreatitis-induced hemolytic anemia and thrombocytopenia, who was managed successfully with plasma exchange, steroids, and rituximab. Clinicians should maintain a high index of suspicion in patients with acute pancreatitis who present with anemia, thrombocytopenia, and schistocytes on peripheral smears, even in the absence of end-organ injuries and with normal ADAMTS13 activity. The early initiation of plasmapheresis can be lifesaving. The timely introduction of rituximab in cases where plasma exchange and steroids are insufficient, despite the ADAMTS13 activity status, may lead to better outcomes.
6.Testicular tumours in children: a single-centre experience.
Sajid ALI ; Tariq LATIF ; Muhammad Ali SHEIKH ; Shazia PERVEEN ; Muhammad BILAL ; Albash SARWAR
Singapore medical journal 2025;66(6):321-326
INTRODUCTION:
Testicular tumours in childhood have diverse characteristics for different age ranges. This study aimed to describe the pattern, presentation and outcomes of primary testicular tumours in a paediatric population.
METHODS:
A retrospective study was conducted from January 2010 to December 2020 on children (≤18 years) with a diagnosis of primary testicular tumour. Baseline demographics, clinical characteristics, pathology, treatment and outcomes of these patients were analysed. The data were entered into IBM SPSS Statistics version 20.0. Chi-square test and Fisher's exact test were applied to find the statistical significance, which was set at P value ≤ 0.05.
RESULTS:
The study included 115 males, with 85 (73.9%) patients in the prepubertal age range with a mean age of 2.53 ± 2.06 years and 30 (26.1%) patients in the postpubertal group with a mean age of 15.73 ± 1.25 years. Yolk sac tumour was the most common (62.6%) histological subtype. Majority (46.1%) of patients had stage I disease on presentation, while 29.6% had stage IV disease. All patients underwent upfront high inguinal radical orchiectomy, which was followed by platinum-based adjuvant chemotherapy in 67% of the patients. The five-year event-free survival and overall survival for all patients were 75% and 91%, respectively.
CONCLUSION
Primary testicular tumours follow a bimodal age distribution pattern. Majority of patients can be cured with platinum-based chemotherapy despite having advanced disease at presentation.
Humans
;
Male
;
Testicular Neoplasms/mortality*
;
Retrospective Studies
;
Adolescent
;
Child
;
Child, Preschool
;
Orchiectomy/methods*
;
Chemotherapy, Adjuvant
;
Treatment Outcome
;
Neoplasm Staging
;
Infant
;
Endodermal Sinus Tumor/therapy*
;
Neoplasms, Germ Cell and Embryonal
7.A novel homozygous splicing mutation in AK7 causes multiple morphological abnormalities of sperm flagella in patients from consanguineous Pakistani families.
Ansar HUSSAIN ; Huan ZHANG ; Muhammad ZUBAIR ; Wasim SHAH ; Khalid KHAN ; Imtiaz ALI ; Yousaf RAZA ; Aurang ZEB ; Tanveer ABBAS ; Nisar AHMED ; Fazal RAHIM ; Ghulam MUSTAFA ; Meftah UDDIN ; Nadeem ULLAH ; Musavir ABBAS ; Muzammil Ahmad KHAN ; Hui MA ; Bo YANG ; Qing-Hua SHI
Asian Journal of Andrology 2025;27(2):189-195
Multiple morphological abnormalities of the flagella (MMAF) represent a severe form of sperm defects leading to asthenozoospermia and male infertility. In this study, we identified a novel homozygous splicing mutation (c.871-4 ACA>A) in the adenylate kinase 7 (AK7) gene by whole-exome sequencing in infertile individuals. Spermatozoa from affected individuals exhibited typical MMAF characteristics, including coiled, bent, short, absent, and irregular flagella. Transmission electron microscopy analysis showed disorganized axonemal structure and abnormal mitochondrial sheets in sperm flagella. Immunofluorescence staining confirmed the absence of AK7 protein from the patients' spermatozoa, validating the pathogenic nature of the mutation. This study provides direct evidence linking the AK7 gene to MMAF-associated asthenozoospermia in humans, expanding the mutational spectrum of AK7 and enhancing our understanding of the genetic basis of male infertility.
Humans
;
Male
;
Sperm Tail/ultrastructure*
;
Homozygote
;
Consanguinity
;
Asthenozoospermia/pathology*
;
Infertility, Male/genetics*
;
Mutation
;
Pakistan
;
Adenylate Kinase/genetics*
;
Adult
;
Pedigree
;
RNA Splicing
;
Exome Sequencing
;
Spermatozoa
8.Novel homozygous SPAG17 variants cause human male infertility through multiple morphological abnormalities of spermatozoal flagella related to axonemal microtubule doublets.
Tao LIU ; Fazal RAHIM ; Meng-Lei YANG ; Meftah UDDIN ; Jing-Wei YE ; Imtiaz ALI ; Yousaf RAZA ; Abu MANSOOR ; Muhammad SHOAIB ; Mujahid HUSSAIN ; Ihsan KHAN ; Basit SHAH ; Asad KHAN ; Ahmad NISAR ; Hui MA ; Bo XU ; Wasim SHAH ; Qing-Hua SHI
Asian Journal of Andrology 2025;27(2):245-253
Male infertility can result from impaired sperm motility caused by multiple morphological abnormalities of the flagella (MMAF). Distinct projections encircling the central microtubules of the spermatozoal axoneme play pivotal roles in flagellar bending and spermatozoal movement. Mammalian sperm-associated antigen 17 ( SPAG17 ) encodes a conserved axonemal protein of cilia and flagella, forming part of the C1a projection of the central apparatus, with functions related to ciliary/flagellar motility, skeletal growth, and male fertility. This study investigated two novel homozygous SPAG17 mutations (M1: NM_206996.2, c.829+1G>T, p.Asp212_Glu276del; and M2: c.2120del, p.Leu707*) identified in four infertile patients from two consanguineous Pakistani families. These patients displayed the MMAF phenotype confirmed by Papanicolaou staining and scanning electron microscopy assays of spermatozoa. Quantitative real-time polymerase chain reaction (PCR) of patients' spermatozoa also revealed a significant decrease in SPAG17 mRNA expression, and immunofluorescence staining showed the absence of SPAG17 protein signals along the flagella. However, no apparent ciliary-related symptoms or skeletal malformations were observed in the chest X-rays of any of the patients. Transmission electron microscopy of axoneme cross-sections from the patients showed incomplete C1a projection and a higher frequency of missing microtubule doublets 1 and 9 compared with those from fertile controls. Immunofluorescence staining and Western blot analyses of spermatogenesis-associated protein 17 (SPATA17), a component of the C1a projection, and sperm-associated antigen 6 (SPAG6), a marker of the spring layer, revealed disrupted expression of both proteins in the patients' spermatozoa. Altogether, these findings demonstrated that SPAG17 maintains the integrity of spermatozoal flagellar axoneme, expanding the phenotypic spectrum of SPAG17 mutations in humans.
Humans
;
Male
;
Infertility, Male/pathology*
;
Sperm Tail/ultrastructure*
;
Homozygote
;
Microtubule-Associated Proteins/genetics*
;
Axoneme/genetics*
;
Spermatozoa/ultrastructure*
;
Adult
;
Mutation
;
Sperm Motility/genetics*
;
Pedigree
;
Microtubules
;
Microtubule Proteins/genetics*
9.Systematic review of validation studies for the use of wearable smartwatches in the screening of atrial fibrillation
Muhammad Samsoor ZARAK ; Sher Ali KHAN ; Harris MAJEED ; Abdul Qahar Khan YASINZAI ; Wadana HAMZAZAI ; Duy CHUNG ; Gregory KOSHKARIAN ; Kevin S. FLEMING
International Journal of Arrhythmia 2024;25(2):11-
WSWs have the potential to reliably and continuously screen for AFib and detect it in a timely manner.The inconclusive results produced by WSWs are a significant problem. Once the inconclusive results are rectified, WSWs may be used for widespread screening of AFib in those people who are at high risk of developing AFib.
10.Role of anticoagulation with apixaban in left‑sided atrial tachycardias
Fraz Ahmed BAIG ; Muhammad Syed ANWAR ; Muhammad Firdous KHAN ; Aroon KUMAR ; F. N. U. MUSKAN ; Jiyanth PARKASH ; Ali KARIM ; Iftikhar AHMED ; Waheed AKHTAR ; Jahanzeb MALIK
International Journal of Arrhythmia 2024;25(2):10-
Background:
Atrial tachycardia poses challenges in patient management due to the associated risks of stroke and systemic embolism. While anticoagulation is recommended in atrial fibrillation (AF), its role in atrial tachycardia remains less defined. This prospective study aimed to evaluate the efficacy and safety of apixaban, a direct oral anticoagulant, in individuals diagnosed with left-sided atrial tachycardias.
Methods:
Patients diagnosed with left-sided atrial tachycardia (n = 439) were observed over 3 years. Baseline characteristics, medication regimens, and clinical outcomes were assessed. Apixaban-treated individuals (n = 213) received standard or reduced dosages, while the control group (n = 226) received standard care. Primary outcomes included stroke, systemic embolism, bleeding, and mortality rates.
Results:
Baseline characteristics were comparable between groups. The apixaban cohort showed a lower incidence of stroke (7.0% vs. 9.3%, p = 0.027) and decreased all-cause mortality (11.7% vs. 12.8%, p = 0.012) compared to controls.No significant differences were found in major bleeding or systemic embolization between groups.
Conclusion
Apixaban demonstrated a potential benefit in reducing stroke and mortality rates in patients with leftsided atrial tachycardia. While requiring further validation, these findings suggest a potential role for apixaban in anticoagulation strategies for atrial tachycardia management.

Result Analysis
Print
Save
E-mail